Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reataâs two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. Source
No articles found.
Catasys has contracted with leading national, regional and local health insurance ...
Catasys has contracted with leading national, r...
Headquartered in Franklin, Tennessee, Acadia Healthcare was established in January...
Headquartered in Franklin, Tennessee, Acadia He...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...
BiondVax is an innovative biopharmaceutical company developing a universal flu vac...
BiondVax is an innovative biopharmaceutical com...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
Join the National Investor Network and get the latest information with your interests in mind.